Xilio Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2022 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Xilio Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2022 to Q2 2024.
Xilio Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 110 %, a 262% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	110	+79.3	+262%	Jun 30, 2024
Q1 2024	71.9	+44.8	+165%	Mar 31, 2024
Q4 2023	41.9	+18.1	+76.3%	Dec 31, 2023
Q3 2023	35.6	+15.1	+73.3%	Sep 30, 2023
Q2 2023	30.3	-6.19	-17%	Jun 30, 2023
Q1 2023	27.2			Mar 31, 2023
Q4 2022	23.8			Dec 31, 2022
Q3 2022	20.6			Sep 30, 2022
Q2 2022	36.5			Jun 30, 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.